Skip to main content

HubXchange

HubXChange logo

Advanced Therapies Xchange - San Francisco - 2025

Page Banner 1

  1. Commercializing Gene Therapy in 2025
    • Commercializing Gene Therapy in 2025
    Pricing, Rare Diseases & Regulatory Navigation
  2. Gene Therapy CMC & Process Development
    • Gene Therapy CMC & Process Development
    Modernizing CMC for Gene Therapies: Speed, Scale & Compliance
  3. Commercializing Gene Therapy in 2025
    • Commercializing Gene Therapy in 2025
    Poster Presentation:
  4. Gene Therapy CMC & Process Development
    • Gene Therapy CMC & Process Development
    Poster Presentation:
  5. Commercializing Gene Therapy in 2025
    • Commercializing Gene Therapy in 2025
    Sponsor Roundtable:
  6. Gene Therapy CMC & Process Development
    • Gene Therapy CMC & Process Development
    Sponsor Roundtable:
  7. Commercializing Gene Therapy in 2025
    • Commercializing Gene Therapy in 2025
    Funding Freeze? VC & Biotech Strategies in a Tough Market
  8. Gene Therapy CMC & Process Development
    • Gene Therapy CMC & Process Development
    Breaking the Bottlenecks: Plasmids, Titers & Stable Cell Lines
  9. Next Gen Vector Engineering & Delivery
    • Next Gen Vector Engineering & Delivery
    Dose Less, Do More: Redefining Specificity in Gene Therapy
    Optimizing tissue tropism, transduction efficiency, and cell-type specificity to lower dosing requir ...
    An Song
    An Song, Chief Research & Translational Development Officer - 4DMT
  10. Next Gen Vector Engineering & Delivery
    • Next Gen Vector Engineering & Delivery
    Poster Presentation:
  11. Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    Poster Presentation:
  12. Allogeneic Access: Engineering the Future of Cell Therapy
    • Allogeneic Access: Engineering the Future of Cell Therapy
    Sponsor Roundtable:
  13. Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    Sponsor Roundtable:
  14. Autologous Therapies in Solid Tumors and Beyond
    • Autologous Therapies in Solid Tumors and Beyond
    Optimizing Autologous Therapies: Commercial & CMC Learnings, Smarter Trials, and Strategic Indication Expansion
    Commercial Lessons from the Front Line: Real-world insights from autologous therapy launches to refi ...
    John Knighton
    John Knighton, Vice President, Cell & Gene Therapy API Development - Johnson & Johnson
  15. Allogeneic Access: Engineering the Future of Cell Therapy
    • Allogeneic Access: Engineering the Future of Cell Therapy
    Proof in the Patient: What CR Outcomes Reveal About T and NK Cell Platform
    Key differences in process design, scalability, and consistency between T cell and NK cell platforms ...
    Faraz Siddiqui
    Faraz Siddiqui, Senior Vice President, Technical Operations - Senti Bio
  16. Allogeneic Access: Engineering the Future of Cell Therapy
    • Allogeneic Access: Engineering the Future of Cell Therapy
    Off-the-Shelf Realities – Where Are We Now? Featuring OmnImmune® and the Evolving Landscape of Allogeneic Cell Therapy
    Exploring lessons from OmnImmune®’s transition from fresh to cryopreserved gamma-delta T cells in re ...
    Bryan Kobel
    Bryan Kobel, Cheif Executive Officer - TC Biopharm
  17. Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    Implementing Potency and NG Release Assays for γδ T Cell Therapies
    Assay design must reflect γδ T cell-specific mechanisms of action (e.g., cytotoxicity, cytokine rele ...
    Christopher Rold
    Christopher Rold, Vice President Vector Development, Analytical Development & Quality Control - Adicet Bio
  18. Next Gen Vector Engineering & Delivery
    • Next Gen Vector Engineering & Delivery
    Sponsor Roundtable:
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    Afternoon Refreshments
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    Morning Refreshments
  21. Next Gen Vector Engineering & Delivery
    • Next Gen Vector Engineering & Delivery
    Innovations in AAV Design and Emerging Alternatives for Gene Delivery
    Engineering capsids with enhanced tissue specificity, immune evasion, and payload capacity. Explorin ...
    Robert Lin
    Robert Lin, Chief Executive Officer - Avista Therapeutics
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    Evening Drinks Reception
  23. Allogeneic Access: Engineering the Future of Cell Therapy
    • Allogeneic Access: Engineering the Future of Cell Therapy
    Poster Presentation:
  24. Autologous Therapies in Solid Tumors and Beyond
    • Autologous Therapies in Solid Tumors and Beyond
    Poster Presentation
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    1-2-1 Meetings / Networking Break
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    1-2-1 Meetings / Networking Break
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    Spotlight Presentation:
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    Networking Lunch
  29. Autologous Therapies in Solid Tumors and Beyond
    • Autologous Therapies in Solid Tumors and Beyond
    Sponsor Roundtable:
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    1-2-1 Meetings / Networking Break
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    1-2-1 Meetings / Networking Break
  32. Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    Advancing CMC for Autologous Cell Therapies: Building Robust, Scalable Platforms
    Streamlining upstream and downstream workflows to support consistent and scalable autologous product ...
    Heike Abeck
    Heike Abeck, Senior Director, BioPartnering & Development Program Lead - Bayer
  33. Autologous Therapies in Solid Tumors and Beyond
    • Autologous Therapies in Solid Tumors and Beyond
    Next-Gen Personalised Cell Therapy Engineering Innovations
    Proprietary tools enhancing potency, precision, and control in autologous cell therapies. Manufactur ...
    Brian Garrison
    Brian Garrison, Vice President of Research - Senti Bio
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    Opening Address & Keynote Presentation:
    • Autologous Therapies in Solid Tumors and Beyond
    • Allogeneic Access: Engineering the Future of Cell Therapy
    • Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
    • Next Gen Vector Engineering & Delivery
    • Gene Therapy CMC & Process Development
    • Commercializing Gene Therapy in 2025
    Registration
Search